Diabetes Insights - Breakthroughs and Innovators

Could weight loss be the key to managing heart failure? In this episode of Diabetes Insights, we dive into the STEP-HFpEF trial, a groundbreaking study exploring the role of GLP-1 receptor agonists in heart failure with preserved ejection fraction (HFpEF).
Host Vivienne Parry speaks with Prof. Melanie Davies (University of Leicester), Prof. Mark Petrie (University of Glasgow), and Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, USA) about the link between obesity, diabetes, and HFpEF, and how weight management could transform heart failure treatment.
With trials already in motion to explore prevention, could we stop HFpEF before it starts?...

In this episode of Diabetes Insights, we explore the power of screening in type 1 diabetes and the potential for early intervention. Host Vivienne Parry speaks with EASD President, Prof. Chantal Mathieu and Prof. Annette Ziegler about groundbreaking research into detecting type 1 diabetes in its earliest stages.

With new disease-modifying therapies on the horizon, early screening is no longer just about preventing complications at diagnosis but it could delay the onset of diabetes and open doors to future treatments.

We discuss how registries, European-wide collaboration, and real-world screening initiatives are shaping the future of early detection, patient monitoring, and...

In this episode, we dive into the critical role of the European Diabetes Forum (EUDF) in shaping diabetes policy across Europe. Host Vivienne Parry speaks with Bart Torbeyns about why bringing together stakeholders - including patient associations, research institutions, healthcare professionals, and industry - is essential to influencing policy makers and improving access to diabetes care.

We discuss the importance of securing diabetes on the EU agenda, tackling the rising costs of diabetes, and addressing misconceptions around obesity and new therapeutics. With European elections reshaping healthcare priorities, how can the diabetes community push for action?

Join us for a compelling...

In this episode of Diabetes Insights, we dive into the latest findings from the FLOW Trial - a groundbreaking trial evaluating the impact of GLP-1 receptor agonists on chronic kidney disease (CKD). This discussion features expert insights from Dr. Peter Rossing, Dr. Richard Pratley and Dr. Katherine Tuttle. The results reveal a 24% reduction in kidney disease progression, an 18% decrease in major cardiovascular events, and a 20% drop in total mortality - findings that could reshape clinical practice. Tune in to explore how this research is transforming diabetes and kidney disease management.